ripk-1-in-3

RIPK1-IN-3 is a RIPK1 inhibitor, with anti-inflammatory proprieties.

RIPK1-IN-30 (compound 24) is a potent RIPK1 inhibitor with an IC50 of 2.01 μM. It demonstrates a protective effect in the HT-29 cell model of TSZ-induced necroptosis, with an EC50 of 6.77 μM.

RIPK1-IN-31 (Compound 36) is a selective allosteric modulator of RIPK1 (Receptor Interacting Protein Kinase 1) with an IC50 value of 16 nM. It holds potential for research in areas such as infections, autoimmune disorders, and neurodegenerative diseases.

RIPK1-IN-32 is an RIPK inhibitor with anti-inflammatory properties. It inhibits nitric oxide (NO) release, with an IC50 of 3.26 μM. Additionally, RIPK1-IN-32 disrupts the RIPK1/NF-κB/MAPK signaling pathway, preventing nuclear translocation of p65 and c-fos, leading to reduced expression of TNF-α and IL-6 and significantly alleviating acute liver injury related to sepsis. This compound is useful for studies on acute liver injury and sepsis.

RIPK1-IN-33 is an orally active RIPK1 inhibitor with excellent blood-brain barrier permeability, exhibiting an IC50 of 0.115 μM. It demonstrates significant anti-ferroptosis activity, radical scavenging capability (IC50= 123.3 μM), and anti-lipid peroxidation effects (IC50= 9.72 μM). In transient middle cerebral artery occlusion (tMCAO) models, it significantly reduces cerebral infarct volume and improves neurological scores. RIPK1-IN-33 is suitable for ischemic stroke research.